Cited 0 times in
Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.